DxTerity today announced that it has completed its move into a new purpose-built headquarters and clinical laboratory at 2848 Columbia St. in Torrance, California. 

The facility combines office space with a laboratory that was constructed from the ground up and designed specifically around DxTerity’s RNA-based genomic testing workflows. The new build gives the company purpose-designed space for sample accessioning, extraction and analysis, and room to add capacity as testing volumes grow. Since occupying the space, DxTerity has completed the regulatory milestones required to run clinical testing from the new location. The New York State Department of Health completed its laboratory inspection in July 2026, and the company completed ISO 13485 recertification for its product development services in August 2026. DxTerity’s laboratory remains CAP-accredited and CLIA-certified. 

DxTerity’s tests — the Type 1 Interferon (IFN-1) assay for systemic lupus erythematosus and the Modular Immune Profile — use RNA measured from a small blood sample to characterize immune system activity, supporting clinicians and biopharma partners working in immune-mediated disease. 

“We are excited to open our new lab to serve growing demand for our Modular Immune Profile test. Our expanded space allows us to process thousands of tests per day and provides the development capacity to build new regulated products and services.”

said Bob Terbrueggen, CEO of DxTerity. 

About DxTerity 

DxTerity’s is pioneering RNA-powered precision diagnostics to help healthcare providers better understand autoimmune diseases and empower patients to live healthier lives through informed, personalized care. DxTerity operates a CAP-accredited, CLIA-certified laboratory in Torrance, California, and holds ISO 13485 certification for its product development services.